AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03009487
Drug: Olmesartan 40 mg, Rosuvastatin 20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: co-administration of Olmetec tab. 40mg(Olmesartan 40mg), Crestor tab. 20mg(Rosuvastatin 20mg) and placebo of Sevikar Tab 10/40mg(Amlodipine/Olmesartan 10/40mg).
Trial: NCT01647958
Drug: PPI
RxNorm normalized name: PPIase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Arm participants will take maximum standard dose of PPI during Initial Study period
Trial: NCT03785145
Drug: MT10109L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MT10109L will be injected into the LCL.
Trial: NCT03785145
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be injected into the LCL.
Trial: NCT00643734
Drug: azithromycin sustained release
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: azithromycin SR 2.0 g by mouth in the form of a slurry for 1 dose
Trial: NCT02970552
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indistinguishable placebo vaginal suppository
Trial: NCT00407745
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02184156
Drug: 4 mL injection of Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02762617
Drug: Placebo intravaginal ring (IVR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Placebo IVR is formulated using preformed flexible tubing, comprised of biomedical medical grade hydrophilic, aliphatic polyurethane, and an inner core compartment comprised of sodium chloride. The ring will be inserted by the study clinician and worn for 28 day intervals for a total of 3 months (84 days). The ring will be removed and replaced with a new ring at each 28 day interval.
Trial: NCT02581072
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied topically once
Trial: NCT01938235
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus and 24-hour infusion of placebo
Trial: NCT00642421
Drug: C2L-OCT-01 PR, 10 or 20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first three injections of study medication will be given at V1 (Day 1), V2 (35 days) and V3 (70 days). Dose titration and/or injection interval adjustment will be allowed during the Treatment Period should any patients have a mean GH concentration below 1.0 ng/mL or above 2.5 ng/mL. Dose titration (10, 20 or 30 mg) and/or injection interval adjustment (4, 5 or 6 weeks) will be allowed at V3, V6 and V9 based on clinical symptoms and the mean GH concentration determined at V2, V5 and V8.
Trial: NCT00642421
Drug: C2L-OCT-01 PR, 20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first three injections of study medication will be given at V1 (Day 1), V2 (Day 35) and V3 (Day 70). Dose titration and/or injection interval adjustment will be allowed during the Treatment Period should any patients have a mean GH concentration below 1.0 ng/mL or above 2.5 ng/mL. Dose titration (10, 20 or 30 mg) and/or injection interval adjustment (4, 5 or 6 weeks) will be allowed at V3, V6 and V9 based on clinical symptoms and the mean GH concentration determined at V2, V5 and V8.
Trial: NCT00561171
Drug: SPP635
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral once daily
Trial: NCT03782480
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intravaginal inserts
Trial: NCT03462836
Drug: IV PCA only apply
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV PCA (fentanyl 10mcg/kg + nefopam (Acupan®) 80mg + Ramosetron (Nasea®) ) apply 30min before end of surgery.
Trial: NCT01647711
Drug: Dose escalation followed by treatment with MTD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed 3+3 dose escalation; expansion of MTD cohort
Trial: NCT01052324
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After topical airway anesthesia with 10 % lidocaine in nostril and oropharyx, 1.5\~2.0 mg of IV midazolam is injected. Awake nasotracheal fiberoptic intubation is performed with target-controlled infusion of remifentanil. Initial effect site concentration is 3.0 ng/ml. Smooth intubation is defined as absence of persistent cough with head elevation and defensive movement of extremities. In case of smooth intubation, effect site concentration is decreased by 0.5 ng/ml for the subsequent case. If intubation is not smooth, effect site concentration is increased by 0.5 ng/ml for the subsequent case. EC50 of remifentanil is determined using Dixon's up-and-down method.
Trial: NCT02999984
Drug: PEG-ADA ERT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-ADA ERT is discontinued at Day +30 (-3/+15 days) after successful engraftment
Trial: NCT02524184
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: an identical placebo per day for 7 days
Trial: NCT03235609
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: fentanyl used with propofol for sedation
Trial: NCT00455962
Drug: Estradiol steroid infusion
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol infusion of 0.1 mcg/kg/hr for 12 hr, 0.135 mcg/kg/hr for 12 hr, 0.165 mcg/kg/hr for 12 hr and 0.2 mcg/kg/hr for 60 hr
Trial: NCT01337765
Drug: BEZ235 + MEK162
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01079819
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, Oral, 0 mg, One daily, 1 Day
Trial: NCT00513617
Drug: Arginine
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Depending on the weight of the child or adult, the patients took any where between 4-10 capsules 2 times a day. Patients weighing less than 45 kilograms were on the low dose active (or placebo) so the capsules were smaller. Patients greater than or equal to 45 kgs were on the high dose active or placebo, so these capsules were larger.
Trial: NCT00513617
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depending on the weight of the child or adult, the patients took any where between 4-10 capsules 2 times a day. Patients weighing less than 45 kilograms were on the low dose active (or placebo) so the capsules were smaller. Patients greater than or equal to 45 kgs were on the high dose active or placebo, so these capsules were larger.
Trial: NCT00865007
Drug: Monotherapy (Lopinavir/ritonavir) + ABC/3TC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRTI sparing regimen
Trial: NCT00204022
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine
Trial: NCT00213057
Drug: Carraguard (PC-515)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00462462
Drug: Ethanol 96% Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00462462
Drug: Ethanol 98% Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02719795
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium chloride solution commonly used in clinical which equal to human plasma osmotic pressure.
Trial: NCT00204789
Drug: Difluoromethylornithine
RxNorm normalized name: α-difluoromethylornithine
DrugBank: Eflornithine (DB06243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02680275
Drug: Dead Sea Peloid Gel
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravaginally
Trial: NCT00894517
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline injected into the prostate on Day 1.
Trial: NCT01470417
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with low risk disease will have an additional two cycles of therapy (4 total cycles) prior to resection.
Trial: NCT00002616
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04249778
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a placebo to match 10 mg/day of dapagliflozin, beginning at hospital discharge, for 26 weeks.
Trial: NCT03223909
Drug: PRO-087
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% sodium hyaluronate, free-preservative 0.18% chondroitin sulphate
Trial: NCT02066337
Drug: placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03451006
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Placebo will be given in divided doses
Trial: NCT03297294
Drug: EMA401
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules, oral
Trial: NCT03297294
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to EMA401 capsules, oral
Trial: NCT01221831
Drug: Estradiol valerate, dienogest and placebo tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 treatment cycles each consisting of 28 days of oral administration as follows:~* Days 1-26: one tablet of Estradiol valerate/dienogest per day~* Days 26-28: one placebo tablet per day
Trial: NCT02506231
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02555982
Drug: BOTOX ® 200 Unités
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients eligible for inclusion will be randomized to one of the two groups:~* Experimental group: 60 patients will receive 2 injections of Btx A (BOTOX - Allergan), one on D0 and one at 12W (into each splenius capitis).~* Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis).
Trial: NCT02555982
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis).
Trial: NCT03988101
Drug: Rosuvastatin 20mg
RxNorm normalized name: ROSUVASTATIN 20MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin 20 mg once daily or equivalent.
Trial: NCT00062101
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02039063
Drug: E6011 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02039063
Drug: E6011 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02039063
Drug: E6011 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02039063
Drug: E6011 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00921284
Drug: NaCl 9/00
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same volume as in the dexmedetomidine group
Trial: NCT01935479
Drug: MN-10-T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous administration of teriparatide acetate
Trial: NCT01935479
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo AK159
Trial: NCT02740179
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eplerenone 50mg by mouth twice daily
Trial: NCT02740179
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo by mouth twice daily
Trial: NCT02593487
Drug: Rosuvastatin 10mg/d group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin 10mg tablet,q.d. for 12 weeks.
Trial: NCT02593487
Drug: Rosuvastatin 20mg/d group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin 20mg tablet,q.d. for 12 weeks.
Trial: NCT01526460
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 mg
Trial: NCT01526460
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no statin loading dose
Trial: NCT01039454
Drug: GSK598809 Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK598809 is being developed for the treatment of substance dependence and potentially other impulse control disorders.
Trial: NCT01039454
Drug: GSK598809 Placebo Capsules
RxNorm normalized name: PLACEBO CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of substance dependence and potentially other impulse control disorders.
Trial: NCT00265772
Drug: MODULEN IBD (R) (specific Enteral Nutrition)
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00265772
Drug: prednisolon
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00749411
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT00749411
Drug: GSK233705/GW642444
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The combination of the long-acting muscarinic antagonist GSK233705 and the long acting beta agonist GW642444 in a single inhaler.
Trial: NCT00913003
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline) bolus similar to the lidocaine infusion minus active drug
Trial: NCT02377466
Drug: Placebo IV infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl matched for the retosiban loading dose and continuous infusion rates
Trial: NCT02104817
Drug: Epanova® (omega-3 carboxylic acids)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunct to statin therapy and diet in high risk adult patients for the prevention and reduction of major adverse cardiovascular events (MACE)
Trial: NCT00000555
Drug: supplementation, food
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000555
Drug: ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00114231
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02137382
Drug: Creon®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: active comparator
Trial: NCT01933919
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet matching to fluvoxamine maleate
Trial: NCT03355352
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sufentail sublingual 15ug nanopills
Trial: NCT02440035
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive intramuscular injection of placebo (sterile formulation buffer) on Day 85 in Group 2. One intramuscular injections of placebo on Day 85 in Group 3. Two intramuscular injections of placebo on Day 1, and Day 85 in Group 4.
Trial: NCT00852917
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One Placebo tablet daily.
Trial: NCT00005090
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg/kg on day -2 (2 days before transplant).
Trial: NCT00005090
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg/m\^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
Trial: NCT02013427
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Take one 500mg naproxen capsule twice a day.
Trial: NCT02013427
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take one placebo capsule twice a day.
Trial: NCT04403516
Drug: Prednisolone Acetate 1%
RxNorm normalized name: PREDNISOLONE ACETATE 1% SUSP,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To reduce post-surgical pain and inflammation in patients who undergo pterygium surgery.
Trial: NCT02270424
Drug: Bufeijianpi granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmono-splenic qi will be given Bufeijianpi granule, twice daily for 52 weeks for lower dosage.
Trial: NCT02270424
Drug: Bufeiyishen granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Bufeiyishen granule, twice daily for 52 weeks for lower dosage.
Trial: NCT03550534
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsule was also obtained from Pharmacy Department, Faculty of Medicine, University of Indonesia. Subjects were randomized to receive calcium carbonate or placebo for 12 weeks.
Trial: NCT03326986
Drug: MK-7252
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/mL or 20 mg/mL of powder for oral suspension administered with a water volume that brings the total ingested volume to approximately 240 mL
Trial: NCT03326986
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo powder for oral suspension administered with a water volume that brings the total ingested volume to approximately 240 mL
Trial: NCT02914769
Drug: Ayahuasca
RxNorm normalized name: ayahuasca
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive a single dose of ayahuasca.
Trial: NCT02914769
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive a single dose of a passive placebo.
Trial: NCT00607295
Drug: clino-san vaginal lubricant
RxNorm normalized name: Trimo San Vaginal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clino-san 2ml vaginal application 3 times per week for 12 weeks
Trial: NCT03082235
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gelatin capsules
Trial: NCT01572519
Drug: Phase 1, Cohort 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type=exact number, unit=mg, number=150, form=capsule, route=oral use. Capsule is taken once daily.
Trial: NCT01572519
Drug: Phase 1, Cohort 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type=exact number, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once daily.
Trial: NCT01572519
Drug: Phase 1, Cohort 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type=exact number, unit=mg, number=450, form=capsule, route=oral use. Capsule is taken once daily.
Trial: NCT01572519
Drug: Phase 1, Cohort 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type=exact number, unit=mg, number=600, form=capsule, route=oral use. Capsule is taken once daily.
Trial: NCT01572519
Drug: Phase 2
RxNorm normalized name: Premphase 28 Day Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-40346527 at the recommended dose determined in Phase 1
Trial: NCT00506506
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00981799
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose will be assigned at study entry, IV as a 30-60 minute infusion (given at hours 3 to 4) on days 1 through 5.
Trial: NCT00981799
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Give between day 29 and 36 or when ANC\>750 and PLTS\>75,000 - whichever comes first (but not prior to day 22) at the dose defined by age below, ideally in conjunction with BM evaluation.~Given intrathecally at the dose defined by age below. 8 mg for patients age greater than or equal to 1, but \<2 years of age 10 mg for patients age greater than or equal to 2, but \<3 years of age 12 mg for patients greater than or equal to 3, but \< 9 years of age 15 mg for patients greater than or equal to \>9 years of age
Trial: NCT01201759
Drug: Placebo twice a day for 30 days. Then Salsalate 2gr BID for 30 days.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will undergo randomization to either 1 month of Salsalate (4.0 g/day) or placebo. An untreated wash-in (1 month) will precede treatment (1 month), and a washout cross-over period (1 month) will follow. After the wash-in month participants will receive either Salsalate or the placebo. The last month will test effects of drug-placebo not examined in month 2.
Trial: NCT04341454
Drug: DWP14012 X mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP14012 X mg, tablet, orally, once daily for 2 weeks
Trial: NCT04341454
Drug: DWP14012 X mg placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP14012 X mg placebo-matching tablet, orally, once daily for 2 weeks
Trial: NCT04341454
Drug: DWP14012 Y mg
RxNorm normalized name: Y
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP14012 Y mg, tablet, orally, twice daily for 2 weeks
Trial: NCT04341454
Drug: DWP14012 Y mg placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP14012 Y mg placebo-matching tablet, orally, twice daily for 2 weeks
Trial: NCT04531787
Drug: Influenza vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: influenza vaccine 0.5 ml intramuscularly each season: 2004-2005, 2005-2006, 2006-2007, 2007-2008 for season specific A/H1N1, A/H3N2, and B antigens
Trial: NCT02480426
Drug: CO2 portograms guidance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIPS creation is performed under the guidance of two-dimensional (2D) CO2 portograms.